利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

51 条记录 (耗时 0.025 秒)

    IL-15 agonist drug combinations for immune therapy
    5.
    发明授权
    IL-15 agonist drug combinations for immune therapy 有权

    公开(公告)号：US11318189B1

    公开(公告)日：2022-05-03

    申请号：US17313285

    申请日：2021-05-06

    申请人： NantCell, Inc.

    发明人： Patrick Soon-Shiong ,  John Lee

    IPC分类号： A61K38/20 ,  A61K31/545 ,  A61K31/546 ,  A61K9/00

    摘要： Methods and pharmaceutical combinations for preventing, reducing the occurrence of, and/or treating an infection in a subject are provided herein. The method includes administering to the subject a therapeutically effective amount of an IL-15 agonist after or concomitantly with administration of a therapeutically effective amount of an antibiotic to the subject. The pharmaceutical combination includes an IL-15 agonist and an antibiotic.

    CD1d and TCR-NKT Cells
    7.
    发明申请
    CD1d and TCR-NKT Cells 审中-公开

    公开(公告)号：US20200270574A1

    公开(公告)日：2020-08-27

    申请号：US16649082

    申请日：2018-09-28

    申请人： NantCell, Inc.

    发明人： Patrick Soon-Shiong ,  Kayvan Niazi

    IPC分类号： C12N5/0783 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C07K14/725 ,  C07K14/705 ,  C12N9/22

    摘要： Compositions, methods and uses of genetically modified NKT cells to induce an NKT cell immune response against tumor or to change a microenvironment of the tumor by suppressing an activity of myeloid-derived suppressor cells are presented. In some embodiments, naive NKT cells are obtained from a patient having a tumor, and are genetically engineered to include a chimeric protein, a T cell receptor, a hybrid T cell receptor replacing the endogenous T cell receptor, or one of CD40L and Fas-L. The naive or genetically modified NKT cells can be administered to a cancer patient to trigger and/or boost immune response against the tumor.